Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New tech program aims to ease stress for asian american Alzheimer's caregivers

NCT ID NCT05615233

First seen Nov 01, 2025 · Last updated Jun 22, 2026 · Updated 38 times

Summary

This study tested a technology-based program called TACAD, designed to support Asian American midlife women who care for a family member with Alzheimer's disease. The program included social media groups, online educational modules, resources, and a virtual reality component. Researchers measured changes in caregiver stress, strain, and quality of life, as well as the well-being of the person receiving care. The goal was to see if this tailored support could improve health outcomes for both caregivers and their loved ones.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALZHEIMER DISEASE are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • University of Texas at Austin

    Austin, Texas, 78712, United States

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Technology-based information and coaching/support program (TACAD)

What this could lead to

If it works, this could point toward a practical, culturally tailored support tool that helps reduce stress and burden for Asian American family caregivers of people with Alzheimer's.

What could go wrong

This was a small, early-stage study with only 54 participants, so results may not apply to all caregivers. The program's benefits may be modest and need further testing in larger, more diverse groups.

Conditions

The condition(s) this trial relates to.

Alzheimer disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.